Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 655

Sort by

Sort Order Select

Journal Articles

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Blood (2024) 144 (1): 61–73.

https://doi.org/10.1182/blood.2024023930

Published: 2024

Includes: Supplemental data

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Jiani Chai, Jui Choudhuri, Qing Wang, Yanan Fang, Yang Shi, Wa Shen, Swati Goel, Ioannis Mantzaris, Aditi Shastri, R. Alejandro Sica, Nishi Shah, Kira Gritsman, Marina Konopleva, Noah Kornblum, Amit Verma, Mendel Goldfinger, Yanhua Wang, Xuejun Tian

Blood (2022) 140 (Supplement 1): 6256–6257.

https://doi.org/10.1182/blood-2022-162857

Published: 2022

Journal Articles

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz

Blood (2022) 140 (Supplement 1): 2371–2373.

https://doi.org/10.1182/blood-2022-169928

Published: 2022

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

Barriers to Autologous Stem Cell Transplantation As Consolidation for Primary Central Nervous System Lymphoma (PCNSL) in HIV Positive Patients in a Minority Rich Cohort in the Bronx, New York

Hiba Narvel, Sindhu Vikash, Charan Thej Reddy Vegivinti, Abdul-Hamid Bazarbachi, M Bakri Hammami, Ansh Krishnachandra Mehta, Daniel K. Reef, Adnan Narvel, Riya Patel, Aditi Shastri, Noah Kornblum, Ioannis Mantzaris, Marina Konopleva, Dennis Cooper, Nishi Shah, Mendel Goldfinger, Ira Braunschweig, Amit Verma, R. Alejandro Sica

Blood (2022) 140 (Supplement 1): 13204–13205.

https://doi.org/10.1182/blood-2022-165704

Published: 2022

Journal Articles

Effects of Glutaminase Inhibition on Venetoclax, Ibrutinib, and AZD-5991 Resistance in Chronic Lymphocytic Leukemia Cell Lines

Natalia Timofeeva, Varsha Gandhi, Marina Konopleva, Mary Ayres

Blood (2022) 140 (Supplement 1): 9862–9864.

https://doi.org/10.1182/blood-2022-170746

Published: 2022

Journal Articles

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3097–3098.

https://doi.org/10.1182/blood-2022-156999

Published: 2022

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Rasoul Pourebrahim, Rafael Heinz Montoya, Edward Ayoub, Hiroki Akiyama, Natalia Baran, Tom Lesluyes, Lauren B Ostermann, Bin Liu, Jo Ishizawa, Joseph D. Khoury, Marina Konopleva, Peter Van Loo, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5876–5878.

https://doi.org/10.1182/blood-2022-167859

Published: 2022

Journal Articles

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Blood (2022) 140 (Supplement 1): 11653–11655.

https://doi.org/10.1182/blood-2022-158112

Published: 2022

Journal Articles

Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Dasatinib and Ponatinib in Lck-Activated T-Cell Acute Lymphoblastic Leukemia

Satoshi Yoshimura, Jianzhong Hu, John C. Panetta, Guoqing Du, Lie Li, Ching-Hon Pui, Marina Konopleva, Nitin Jain, Jun J.J. Yang

Blood (2022) 140 (Supplement 1): 8840–8841.

https://doi.org/10.1182/blood-2022-169363

Published: 2022

Journal Articles

Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)

Betul Oran, Richard E Champlin, Peter F Thall, Jessica M McCarty, Wen Zhang, David Marin, Rohtesh S. Mehta, Amin M Alousi, Gheath Alatrash, Uday R Popat, Hagop Kantarjian, Qaiser Bashir, Elizabeth J Shpall, Marina Konopleva

Blood (2022) 140 (Supplement 1): 10561–10562.

https://doi.org/10.1182/blood-2022-159312

Published: 2022

Journal Articles

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Nitin Jain, Elias Jabbour, Ibrahim Aldoss, Marina Konopleva, Nicholas Short, Anthony S. Stein, Naveen Pemmaraju, Philip A. Thompson, Farhad Ravandi, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 521–522.

https://doi.org/10.1182/blood-2022-170730

Published: 2022

Journal Articles

Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML

Bianca L Rivera, Samarpana Chakraborty, Yang Shi, Hui Zhang, Gaurav S Choudhary, Shanisha Gordon, Kith Pradhan, Bowen Fu, Isidora Tosic, Rongbao Zhao, Mendel Goldfinger, Ioannis Mantzaris, Milagros Carbajal, Nandini Ramachandra, Marina Konopleva, David Frank, Yogenthiran Saunthararajah, Amit Verma, Aditi Shastri

Blood (2022) 140 (Supplement 1): 6892–6893.

https://doi.org/10.1182/blood-2022-163255

Published: 2022

Journal Articles

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Emmanuel Almanza Huante, Elias Jabbour, Marina Konopleva, Cesar Nunez, Sergej Konoplev, Nicholas Short, Naveen Pemmaraju, Fatima Zahra Jelloul, Guilin Tang, Hagop Kantarjian, Nitin Jain

Blood (2022) 140 (Supplement 1): 3178–3180.

https://doi.org/10.1182/blood-2022-169370

Published: 2022

NARROW

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Barriers to Autologous Stem Cell Transplantation As Consolidation for Primary Central Nervous System Lymphoma (PCNSL) in HIV Positive Patients in a Minority Rich Cohort in the Bronx, New York

Effects of Glutaminase Inhibition on Venetoclax, Ibrutinib, and AZD-5991 Resistance in Chronic Lymphocytic Leukemia Cell Lines

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Dasatinib and Ponatinib in Lck-Activated T-Cell Acute Lymphoblastic Leukemia

Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only